Peramivir: an intravenous neuraminidase inhibitor

• Published in: Expert opinion on pharmacotherapy Vol. 16; no. 12; p. 1889
• Main Authors: McLaughlin, Milena M, Skoglund, Erik W, Ison, Michael G
• Format: Journal Article
• Language: English
• Published: England 13.08.2015
• Subjects: Animals; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Clinical Trials as Topic; Cyclopentanes - administration & dosage; Cyclopentanes - therapeutic use; Drug Resistance, Viral; Guanidines - administration & dosage; Guanidines - therapeutic use; Humans; Influenza, Human - drug therapy; Injections, Intravenous; Neuraminidase - antagonists & inhibitors; influenza; neuraminidase inhibitor; peramivir; zanamivir; oseltamivir
• ISSN: 1744-7666
• DOI: 10.1517/14656566.2015.1066336

Peramivir (BCX-1812, RWJ-270201) is a highly selective inhibitor of influenza A and B neuraminidase that has recently been approved in the USA by the FDA to treat acute, uncomplicated influenza in adults. This review examines the discovery and development of peramavir as well as its role in the treatment of influenza. Peramivir is currently the only FDA-approved anti-influenza agent that can be given as an intravenous injection, granting it a unique role in therapy with the potential to improve adherence and outcomes in patients who are unable to tolerate oral agents. In vitro, animal, human and safety data are presented as well as information regarding special populations, resistance and drug approval. Clinical trial data support the use of peramivir to relieve influenza symptoms in acute, uncomplicated influenza, with improvements over placebo similar to those of other approved anti-influenza treatments. The ability to give a one-time injectable dose offers improved adherence over currently available oral regimens. While not approved for hospitalized patients, available data suggest that multiple dose peramivir may also have a role in treatment of severally ill, hospitalized patients. Supportive data for the use of peramivir in special patient populations such as pediatrics and those especially at-risk to develop severe influenza symptoms are promising; however, they require further study.